| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
49,820,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ALX Oncology Holdings is a holding company. Through its subsidiaries, Co. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on capabilities in protein engineering and oncology led by the CD47 blocker, evorpacept. Co.'s primary product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction and breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
92,233 |
167,233 |
167,233 |
213,633 |
| Total Buy Value |
$99,353 |
$157,756 |
$157,756 |
$356,269 |
| Total People Bought |
1 |
2 |
2 |
4 |
| Total Buy Transactions |
2 |
3 |
3 |
6 |
| Total Shares Sold |
0 |
6,536 |
25,014 |
204,655 |
| Total Sell Value |
$0 |
$3,480 |
$31,432 |
$2,155,671 |
| Total People Sold |
0 |
2 |
3 |
5 |
| Total Sell Transactions |
0 |
4 |
10 |
28 |
| End Date |
2025-09-04 |
2025-06-03 |
2024-12-03 |
2023-12-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lettmann Jason |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-09-17 |
4 |
B |
$1.08 |
$76,892 |
D/D |
71,163 |
305,121 |
0.01 |
- |
|
| Lettmann Jason |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-09-16 |
4 |
B |
$1.07 |
$22,461 |
D/D |
21,070 |
233,958 |
0.01 |
- |
|
| Shantharam Harish |
Chief Financial Officer |
• – – |
2025-08-18 |
4 |
B |
$0.78 |
$58,403 |
D/D |
75,000 |
75,000 |
0.01 |
- |
|
| Lettmann Jason |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-08-15 |
4 |
S |
$0.64 |
$1,525 |
D/D |
(2,382) |
212,888 |
|
- |
|
| Pinto Shelly |
SVP, FINANCE AND CAO |
• – – |
2025-08-15 |
4 |
S |
$0.64 |
$391 |
D/D |
(611) |
89,198 |
|
- |
|
| Pinto Shelly |
SVP, FINANCE AND CAO |
• – – |
2025-07-07 |
4 |
S |
$0.45 |
$905 |
D/D |
(2,011) |
86,809 |
|
- |
|
| Pinto Shelly |
SVP, FINANCE AND CAO |
• – – |
2025-06-30 |
4 |
S |
$0.43 |
$659 |
D/D |
(1,532) |
88,820 |
|
- |
|
| Pinto Shelly |
SVP, FINANCE AND CAO |
• – – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
90,352 |
|
- |
|
| Lettmann Jason |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
42,000 |
212,270 |
|
- |
|
| Pinto Shelly |
SVP, FINANCE AND CAO |
• – – |
2025-02-19 |
4 |
S |
$1.15 |
$633 |
D/D |
(550) |
87,352 |
|
- |
|
| Pons Jaume |
PRESIDENT & CSO |
• – – |
2025-02-19 |
4 |
S |
$1.15 |
$1,525 |
D/D |
(1,326) |
579,388 |
|
- |
|
| Lettmann Jason |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-02-19 |
4 |
S |
$1.15 |
$2,483 |
D/D |
(2,159) |
170,270 |
|
- |
|
| Klencke Barbara |
|
– • – |
2025-01-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
60,000 |
|
- |
|
| Klencke Barbara |
|
– • – |
2025-01-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
60,000 |
|
- |
|
| Pinto Shelly |
Interim CFO |
• – – |
2025-01-06 |
4 |
S |
$1.80 |
$3,998 |
D/D |
(2,221) |
87,902 |
|
- |
|
| Pinto Shelly |
Interim CFO |
• – – |
2024-12-30 |
4 |
S |
$1.58 |
$2,253 |
D/D |
(1,426) |
90,123 |
|
- |
|
| Pons Jaume |
PRESIDENT & CSO |
• – – |
2024-12-30 |
4 |
S |
$1.58 |
$17,060 |
D/D |
(10,796) |
580,714 |
|
- |
|
| Hemrajani Rekha |
|
– • – |
2024-12-02 |
4 |
B |
$1.55 |
$46,404 |
D/D |
30,000 |
33,000 |
0.01 |
- |
|
| Pons Jaume |
PRESIDENT & CSO |
• – – |
2024-08-14 |
4 |
S |
$2.58 |
$4,997 |
D/D |
(1,937) |
591,510 |
|
- |
|
| Garcia Peter S |
CHIEF FINANCIAL OFFICER |
• – – |
2024-08-14 |
4 |
D |
$2.58 |
$1,963 |
D/D |
(761) |
121,516 |
|
- |
|
| Lettmann Jason |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-08-14 |
4 |
D |
$2.58 |
$5,653 |
D/D |
(2,191) |
169,429 |
|
- |
|
| Pinto Shelly |
SVP, FINANCE AND CAO |
• – – |
2024-08-14 |
4 |
S |
$2.58 |
$1,455 |
D/D |
(564) |
91,549 |
|
- |
|
| Randolph Sophia |
CHIEF MEDICAL OFFICER |
• – – |
2024-08-14 |
4 |
S |
$2.58 |
$3,522 |
D/D |
(1,365) |
325,711 |
|
- |
|
| Pons Jaume |
PRESIDENT & CSO |
• • – |
2024-07-11 |
4 |
AS |
$7.90 |
$158,076 |
D/D |
(20,000) |
593,447 |
|
- |
|
| Pons Jaume |
PRESIDENT & CSO |
• • – |
2024-07-11 |
4 |
OE |
$0.99 |
$19,800 |
D/D |
20,000 |
613,447 |
|
- |
|
137 Records found
|
|
Page 1 of 6 |
|
|
